Prevention of breast cancer using SERMs and aromatase inhibitors

Area of Science:

• Oncology
• Endocrinology

Background:

• Breast cancer remains a significant health concern for women globally.
• Current treatments have limitations, highlighting the need for effective prevention strategies.
• Estrogen plays a key role in breast cancer development.

Purpose of the Study:

• To review available data on selective estrogen receptor modulators (SERMs) for breast cancer prevention.
• To outline the efficacy of aromatase inhibitors as an alternative estrogen-blocking strategy.
• To compare the chemopreventive potential and side-effect profiles of different agents.

Main Methods:

• Review of prospective, placebo-controlled trials involving tamoxifen and other SERMs.
• Analysis of data on raloxifene and aromatase inhibitors in breast cancer prevention.
• Comparison of efficacy and safety profiles of investigational agents.

Main Results:

• Tamoxifen has demonstrated efficacy in reducing invasive breast cancer and preinvasive lesions.
• Ongoing trials are evaluating newer SERMs for superior chemopreventive effects and better tolerability.
• Aromatase inhibitors offer a distinct mechanism for estrogen antagonism in prevention.

Conclusions:

• Estrogen-targeting strategies, including SERMs and aromatase inhibitors, are a logical approach to breast cancer prevention.
• Further research is needed to establish the optimal agents and their long-term benefits.
• The development of novel SERMs and aromatase inhibitors holds potential for reducing breast cancer incidence.